HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Sodium–glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

This item is licensed under: Creative Commons Attribution-NonCommercial 4.0 International

Files in This Item:
jdi.13335.pdf717.91 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/80387

Title: Sodium–glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes
Authors: Chiba, Koki Browse this author
Nomoto, Hiroshi Browse this author →KAKEN DB
Nakamura, Akinobu Browse this author →KAKEN DB
Cho, Kyu Yong Browse this author
Yamashita, Kumiko Browse this author
Shibayama, Yui Browse this author
Miya, Aika Browse this author
Kameda, Hiraku Browse this author →KAKEN DB
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: SGLT2 inhibitor
type 1 diabetes
glucose variability
Issue Date: Feb-2021
Publisher: John Wiley & Sons
Journal Title: Journal of Diabetes Investigation
Volume: 12
Issue: 2
Start Page: 176
End Page: 183
Publisher DOI: 10.1111/jdi.13335
Abstract: Introduction: SGLT2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes (T1DM). Materials and Methods: Patients with T1DM who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day‐to‐day glucose variability, as the primary endpoint, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring (CGM). Results: Fifty‐one patients (37 women; mean age 52.7 years) were included. HbA1c and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 ± 26.6 to 38.7 ± 24.3 units/day). CGM data were obtained from 30 patients. P25/P75 decreased by 17.6 ± 20.7% during SGLT2i treatment (P <0.001). The percentage of time per day within the target glucose range of 70?180 mg/dL significantly increased (from 42.2% to 55.5%, P <0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis. Conclusions: SGLT2i improved day‐to‐day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with T1DM, and reduced HbA1c, body mass, and the required insulin dose.
Rights: http://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/80387
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University